越南慢性髓性白血病患者BCR::ABL1激酶结构域突变特征

IF 0.7 Q4 HEMATOLOGY
Phu Chi Dung , Huynh Duc Vinh Phu , Cao Van Dong , Chau Thuy Ha , Nguyen Thi Thanh Ha , Tran Ngoc Xuan Thy , Le Vu Ha Thanh , Huynh Nghia , Nguyen Tan Binh , Hoang Anh Vu , Phan Thi Xinh , Cao Sy Luan
{"title":"越南慢性髓性白血病患者BCR::ABL1激酶结构域突变特征","authors":"Phu Chi Dung ,&nbsp;Huynh Duc Vinh Phu ,&nbsp;Cao Van Dong ,&nbsp;Chau Thuy Ha ,&nbsp;Nguyen Thi Thanh Ha ,&nbsp;Tran Ngoc Xuan Thy ,&nbsp;Le Vu Ha Thanh ,&nbsp;Huynh Nghia ,&nbsp;Nguyen Tan Binh ,&nbsp;Hoang Anh Vu ,&nbsp;Phan Thi Xinh ,&nbsp;Cao Sy Luan","doi":"10.1016/j.lrr.2025.100512","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>BCR::ABL1</em> kinase domain (KD) mutations represent a common cause of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients. The frequency and pattern of KD mutations differ among populations worldwide. However, the characteristics of KD mutations in Vietnamese patients remain unclear.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of CML patients at Blood Transfusion Hematology Hospital who were resistant to frontline imatinib between Oct 2010 and Oct 2018. Direct sequencing technique was performed to detect KD mutations.</div></div><div><h3>Results</h3><div>488 imatinib-resistant CML patients were included in our study. The median age of the patients was 39, with the majority (82.1 %) diagnosed with chronic phase at the time of resistance. KD mutations were identified in 173 (35.5 %) patients, with 8 cases involving novel variants. The KD mutations predominantly localized within the P-loop of BCR::ABL1 (36.7 %). G250E was the most common mutation, followed by Y253H, M351T, and M244V. In particular, Y253H, T315I, F359V, F317L, E355G, and Q252H were frequently observed in accelerated phase and blast crisis patients. In addition, M244V, T315I, E459K, E255K, F317L, Q252H and E355G were all observed in primary resistant patients.</div></div><div><h3>Conclusion</h3><div>The emergence of certain specific mutations may serve as the early indicators of leukemic progression, necessitating prompt intervention for better disease control.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100512"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients\",\"authors\":\"Phu Chi Dung ,&nbsp;Huynh Duc Vinh Phu ,&nbsp;Cao Van Dong ,&nbsp;Chau Thuy Ha ,&nbsp;Nguyen Thi Thanh Ha ,&nbsp;Tran Ngoc Xuan Thy ,&nbsp;Le Vu Ha Thanh ,&nbsp;Huynh Nghia ,&nbsp;Nguyen Tan Binh ,&nbsp;Hoang Anh Vu ,&nbsp;Phan Thi Xinh ,&nbsp;Cao Sy Luan\",\"doi\":\"10.1016/j.lrr.2025.100512\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div><em>BCR::ABL1</em> kinase domain (KD) mutations represent a common cause of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients. The frequency and pattern of KD mutations differ among populations worldwide. However, the characteristics of KD mutations in Vietnamese patients remain unclear.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of CML patients at Blood Transfusion Hematology Hospital who were resistant to frontline imatinib between Oct 2010 and Oct 2018. Direct sequencing technique was performed to detect KD mutations.</div></div><div><h3>Results</h3><div>488 imatinib-resistant CML patients were included in our study. The median age of the patients was 39, with the majority (82.1 %) diagnosed with chronic phase at the time of resistance. KD mutations were identified in 173 (35.5 %) patients, with 8 cases involving novel variants. The KD mutations predominantly localized within the P-loop of BCR::ABL1 (36.7 %). G250E was the most common mutation, followed by Y253H, M351T, and M244V. In particular, Y253H, T315I, F359V, F317L, E355G, and Q252H were frequently observed in accelerated phase and blast crisis patients. In addition, M244V, T315I, E459K, E255K, F317L, Q252H and E355G were all observed in primary resistant patients.</div></div><div><h3>Conclusion</h3><div>The emergence of certain specific mutations may serve as the early indicators of leukemic progression, necessitating prompt intervention for better disease control.</div></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":\"23 \",\"pages\":\"Article 100512\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048925000147\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048925000147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

dbcr:ABL1激酶结构域(KD)突变是慢性髓性白血病(CML)患者对酪氨酸激酶抑制剂耐药的常见原因。KD突变的频率和模式在世界各地的人群中有所不同。然而,越南患者KD突变的特征尚不清楚。方法对2010年10月至2018年10月输血血液科医院一线伊马替尼耐药CML患者进行回顾性队列研究。采用直接测序技术检测KD突变。结果共纳入488例伊马替尼耐药CML患者。患者的中位年龄为39岁,大多数(82.1%)在耐药时诊断为慢性期。在173例(35.5%)患者中发现KD突变,其中8例涉及新变体。KD突变主要发生在BCR::ABL1的p环内(36.7%)。G250E是最常见的突变,其次是Y253H、M351T和M244V。其中Y253H、T315I、F359V、F317L、E355G、Q252H在加速期和爆炸危象患者中较多出现。此外,M244V、T315I、E459K、E255K、F317L、Q252H和E355G均出现在原发性耐药患者中。结论某些特异性突变的出现可能是白血病进展的早期指标,需要及时干预以更好地控制疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients

Background

BCR::ABL1 kinase domain (KD) mutations represent a common cause of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients. The frequency and pattern of KD mutations differ among populations worldwide. However, the characteristics of KD mutations in Vietnamese patients remain unclear.

Methods

A retrospective cohort study of CML patients at Blood Transfusion Hematology Hospital who were resistant to frontline imatinib between Oct 2010 and Oct 2018. Direct sequencing technique was performed to detect KD mutations.

Results

488 imatinib-resistant CML patients were included in our study. The median age of the patients was 39, with the majority (82.1 %) diagnosed with chronic phase at the time of resistance. KD mutations were identified in 173 (35.5 %) patients, with 8 cases involving novel variants. The KD mutations predominantly localized within the P-loop of BCR::ABL1 (36.7 %). G250E was the most common mutation, followed by Y253H, M351T, and M244V. In particular, Y253H, T315I, F359V, F317L, E355G, and Q252H were frequently observed in accelerated phase and blast crisis patients. In addition, M244V, T315I, E459K, E255K, F317L, Q252H and E355G were all observed in primary resistant patients.

Conclusion

The emergence of certain specific mutations may serve as the early indicators of leukemic progression, necessitating prompt intervention for better disease control.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信